These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24303008)

  • 1. The gastric CB1 receptor modulates ghrelin production through the mTOR pathway to regulate food intake.
    Senin LL; Al-Massadi O; Folgueira C; Castelao C; Pardo M; Barja-Fernandez S; Roca-Rivada A; Amil M; Crujeiras AB; Garcia-Caballero T; Gabellieri E; Leis R; Dieguez C; Pagotto U; Casanueva FF; Seoane LM
    PLoS One; 2013; 8(11):e80339. PubMed ID: 24303008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inhibition of cannabinoid receptor 1 stimulates gastric release of nesfatin-1 via the mTOR pathway.
    Folgueira C; Barja-Fernandez S; Prado L; Al-Massadi O; Castelao C; Pena-Leon V; Gonzalez-Saenz P; Baltar J; Baamonde I; Leis R; Dieguez C; Pagotto U; Casanueva FF; Tovar SA; Nogueiras R; Seoane LM
    World J Gastroenterol; 2017 Sep; 23(35):6403-6411. PubMed ID: 29085189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ghrelin-induced orexigenic effect in rats depends on the metabolic status and is counteracted by peripheral CB1 receptor antagonism.
    Alen F; Crespo I; Ramírez-López MT; Jagerovic N; Goya P; de Fonseca FR; de Heras RG; Orio L
    PLoS One; 2013; 8(4):e60918. PubMed ID: 23565287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system.
    Kola B; Farkas I; Christ-Crain M; Wittmann G; Lolli F; Amin F; Harvey-White J; Liposits Z; Kunos G; Grossman AB; Fekete C; Korbonits M
    PLoS One; 2008 Mar; 3(3):e1797. PubMed ID: 18335063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral endocannabinoid system-mediated actions of rimonabant on growth hormone secretion are ghrelin-dependent.
    Al-Massadi O; Gabellieri E; Trujillo ML; Señaris R; Pagotto U; Pasquali R; Casanueva FF; Seoane LM
    J Neuroendocrinol; 2010 Nov; 22(11):1127-36. PubMed ID: 20807320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cannabinoid CB1 receptor and mTORC1 signalling pathways interact to modulate glucose homeostasis in mice.
    Bermudez-Silva FJ; Romero-Zerbo SY; Haissaguerre M; Ruz-Maldonado I; Lhamyani S; El Bekay R; Tabarin A; Marsicano G; Cota D
    Dis Model Mech; 2016 Jan; 9(1):51-61. PubMed ID: 26563389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release.
    Kola B; Wittman G; Bodnár I; Amin F; Lim CT; Oláh M; Christ-Crain M; Lolli F; van Thuijl H; Leontiou CA; Füzesi T; Dalino P; Isidori AM; Harvey-White J; Kunos G; Nagy GM; Grossman AB; Fekete C; Korbonits M
    FASEB J; 2013 Dec; 27(12):5112-21. PubMed ID: 23982145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential modulation of endogenous cannabinoid CB1 and CB2 receptors in spontaneous and splice variants of ghrelin-induced food intake in conscious rats.
    Ting CH; Chi CW; Li CP; Chen CY
    Nutrition; 2015 Jan; 31(1):230-5. PubMed ID: 25466669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoid receptor 1 modulates the autophagic flux independent of mTOR- and BECLIN1-complex.
    Hiebel C; Kromm T; Stark M; Behl C
    J Neurochem; 2014 Nov; 131(4):484-97. PubMed ID: 25066892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior.
    Duarte C; Alonso R; Bichet N; Cohen C; Soubrié P; Thiébot MH
    Neuropsychopharmacology; 2004 May; 29(5):911-20. PubMed ID: 14694354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerance to hypophagia induced by prolonged treatment with a CB1 antagonist is related to the reversion of anorexigenic neuropeptide gene expression in the hypothalamus.
    Rorato R; Miyahara C; Antunes-Rodrigues J; Elias LL
    Regul Pept; 2013 Mar; 182():12-8. PubMed ID: 23327999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
    Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
    J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation.
    Zhang L; Lee NJ; Nguyen AD; Enriquez RF; Riepler SJ; Stehrer B; Yulyaningsih E; Lin S; Shi YC; Baldock PA; Herzog H; Sainsbury A
    Diabetes Obes Metab; 2010 Jul; 12(7):591-603. PubMed ID: 20590734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastric mammalian target of rapamycin signaling regulates ghrelin production and food intake.
    Xu G; Li Y; An W; Li S; Guan Y; Wang N; Tang C; Wang X; Zhu Y; Li X; Mulholland MW; Zhang W
    Endocrinology; 2009 Aug; 150(8):3637-44. PubMed ID: 19406939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid CB(1) receptor and gastric acid secretion.
    Borrelli F
    Dig Dis Sci; 2007 Nov; 52(11):3102-3. PubMed ID: 17404883
    [No Abstract]   [Full Text] [Related]  

  • 16. Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide.
    Cani PD; Montoya ML; Neyrinck AM; Delzenne NM; Lambert DM
    Br J Nutr; 2004 Nov; 92(5):757-61. PubMed ID: 15533263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-flavoured beverage in rats.
    Maccioni P; Pes D; Carai MA; Gessa GL; Colombo G
    Behav Pharmacol; 2008 May; 19(3):197-209. PubMed ID: 18469537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High fat diet induced obesity alters endocannabinoid and ghrelin mediated regulation of components of the endocannabinoid system in nodose ganglia.
    Christie S; O'Rielly R; Li H; Wittert GA; Page AJ
    Peptides; 2020 Sep; 131():170371. PubMed ID: 32659299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats.
    Kunz I; Meier MK; Bourson A; Fisseha M; Schilling W
    Int J Obes (Lond); 2008 May; 32(5):863-70. PubMed ID: 18253160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
    Serrano A; Del Arco I; Javier Pavón F; Macías M; Perez-Valero V; Rodríguez de Fonseca F
    Neuropharmacology; 2008 Jan; 54(1):226-34. PubMed ID: 17467748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.